RYTM vs. LMN.V

Last updated Jun 13, 2026

RYTM (Rhythm Pharmaceuticals, Inc.) and LMN.V (Lumine Group Inc) are both stocks. RYTM operates in Biotechnology (Healthcare), while LMN.V operates in Software - Application (Technology). Over the past 3 years, RYTM returned 70.57%/yr vs 6.58%/yr for LMN.V. At a 0.07 correlation, their price movements are largely independent.

Performance

RYTM vs. LMN.V - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Rhythm Pharmaceuticals, Inc. (RYTM) and Lumine Group Inc (LMN.V). The values are adjusted to include any dividend payments, if applicable.

Different Trading Currencies

RYTM is traded in USD, while LMN.V is traded in CAD. To make them comparable, the LMN.V values have been converted to USD using the latest available exchange rates.

Returns By Period

In the year-to-date period, RYTM achieves a -17.43% return, which is significantly lower than LMN.V's -15.80% return.

RYTM

• 1D: 0.82%
• 1M: -5.70%
• YTD: -17.43%
• 6M: -22.17%
• 1Y: 40.24%
• 3Y*: 70.57%
• 5Y*: 35.88%
• 10Y*: —

LMN.V

• 1D: 0.75%
• 1M: 14.68%
• YTD: -15.80%
• 6M: -18.48%
• 1Y: -50.33%
• 3Y*: 6.58%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

RYTM vs. LMN.V - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023
RYTM Rhythm Pharmaceuticals, Inc.	-17.43%	91.21%	21.78%	167.27%
LMN.V Lumine Group Inc	-15.80%	-30.87%	26.85%	90.78%

Correlation

The correlation between RYTM and LMN.V is 0.03, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.03
Correlation (3Y) Calculated over the trailing 3-year period	0.07
Correlation (All Time) Calculated using the full available price history since Mar 24, 2023	0.07

Fundamentals

Market Cap RYTM : $6.01B LMN.V : CA$5.99B
EPS RYTM : -$3.10 LMN.V : $0.48
PS Ratio RYTM : 26.75 LMN.V : 5.18
PB Ratio RYTM : 732.99 LMN.V : 5.16
Total Revenue (TTM) RYTM : $217.17M LMN.V : $792.89M
Gross Profit (TTM) RYTM : $194.16M LMN.V : $271.95M
EBITDA (TTM) RYTM : -$182.86M LMN.V : $253.96M

Return for Risk

RYTM vs. LMN.V — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RYTM

RYTM Risk / Return Rank: 67
RYTM Sharpe Ratio Rank: 66
RYTM Sortino Ratio Rank: 71
RYTM Omega Ratio Rank: 66
RYTM Calmar Ratio Rank: 66
RYTM Martin Ratio Rank: 66

LMN.V

LMN.V Risk / Return Rank: 11
LMN.V Sharpe Ratio Rank: 7
LMN.V Sortino Ratio Rank: 6
LMN.V Omega Ratio Rank: 8
LMN.V Calmar Ratio Rank: 15
LMN.V Martin Ratio Rank: 20

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RYTM vs. LMN.V - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Rhythm Pharmaceuticals, Inc. (RYTM) and Lumine Group Inc (LMN.V). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	RYTM	LMN.V	Difference
Sharpe ratio: Return per unit of total volatility	0.71	-0.95	+1.66
Sortino ratio: Return per unit of downside risk	1.64	-1.61	+3.26
Omega ratio: Gain probability vs. loss probability	1.19	0.83	+0.37
Calmar ratio: Return relative to maximum drawdown	1.14	-0.76	+1.90
Martin ratio: Return relative to average drawdown	2.64	-1.09	+3.73

RYTM vs. LMN.V - Sharpe Ratio Comparison

The current RYTM Sharpe Ratio is 0.71, which is higher than the LMN.V Sharpe Ratio of -0.95. The chart below compares the historical Sharpe Ratios of RYTM and LMN.V, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

RYTM vs. LMN.V - Drawdown Comparison

The maximum RYTM drawdown since its inception was -92.10%, which is greater than LMN.V's maximum drawdown of -66.63%. Use the drawdown chart below to compare losses from any high point for RYTM and LMN.V.

Drawdown Indicators

	RYTM	LMN.V	Difference
Max Drawdown Largest peak-to-trough decline	-92.10%	-66.63%	-25.47%
Max Drawdown (1Y) Largest decline over 1 year	-35.54%	-66.63%	+31.09%
Max Drawdown (3Y) Largest decline over 3 years	-35.54%	-66.63%	+31.09%
Max Drawdown (5Y) Largest decline over 5 years	-85.49%	—	—
Current Drawdown Current decline from peak	-24.86%	-58.05%	+33.19%
Average Drawdown Average peak-to-trough decline	-32.15%	-18.14%	-14.01%
Ulcer Index Depth and duration of drawdowns from previous peaks	15.31%	46.16%	-30.85%

Volatility

RYTM vs. LMN.V - Volatility Comparison

The current volatility for Rhythm Pharmaceuticals, Inc. (RYTM) is 11.87%, while Lumine Group Inc (LMN.V) has a volatility of 12.52%. This indicates that RYTM experiences smaller price fluctuations and is considered to be less risky than LMN.V based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	RYTM	LMN.V	Difference
Volatility (1M) Calculated over the trailing 1-month period	11.87%	12.52%	-0.65%
Volatility (6M) Calculated over the trailing 6-month period	36.41%	39.07%	-2.66%
Volatility (1Y) Calculated over the trailing 1-year period	57.20%	53.20%	+4.00%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	76.39%	45.29%	+31.10%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	71.57%	45.29%	+26.28%

Dividends

RYTM vs. LMN.V - Dividend Comparison

Neither RYTM nor LMN.V has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

RYTM vs. LMN.V - Profitability Comparison

The chart below illustrates the profitability comparison between Rhythm Pharmaceuticals, Inc. and Lumine Group Inc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

RYTM - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Rhythm Pharmaceuticals, Inc. reported a gross profit of 52.96M and revenue of 60.11M. Therefore, the gross margin over that period was 88.1%.

LMN.V - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Lumine Group Inc reported a gross profit of 43.76M and revenue of 204.93M. Therefore, the gross margin over that period was 21.4%.

RYTM - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Rhythm Pharmaceuticals, Inc. reported an operating income of -52.36M and revenue of 60.11M, resulting in an operating margin of -87.1%.

LMN.V - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Lumine Group Inc reported an operating income of 28.74M and revenue of 204.93M, resulting in an operating margin of 14.0%.

RYTM - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Rhythm Pharmaceuticals, Inc. reported a net income of -56.74M and revenue of 60.11M, resulting in a net margin of -94.4%.

LMN.V - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Lumine Group Inc reported a net income of 18.70M and revenue of 204.93M, resulting in a net margin of 9.1%.

Frequently Asked Questions

Can I hold both RYTM and LMN.V in my portfolio?

RYTM and LMN.V have a correlation of 0.03, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.